A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Resistant/Refractory Multiple Myeloma

Trial Profile

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Resistant/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Selinexor (Primary) ; Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms STOMP
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the company has dosed patients in a newly initiated SDd arm.The SDd arm of the STOMP study is expected to enroll up to 16 patients and the Company expects to report top-line data in the first half of 2018.
    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the company expects to report updated data on all oral regimens by year end 2017.
    • 10 Apr 2017 Time frame has changed from 2 months to 12 months,number of arms changed from 2 to 3 and planned patient number chenged from 201 to262.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top